The Pirbright Institute, Pirbright, Woking, United Kingdom.
ViroVet NV, Leuven, Belgium.
mSphere. 2022 Dec 21;7(6):e0037822. doi: 10.1128/msphere.00378-22. Epub 2022 Nov 1.
African swine fever virus (ASFV) causes a highly contagious hemorrhagic disease with case fatality rates approaching 100% in domestic pigs. ASFV is responsible for substantial economic losses, but despite ongoing efforts, no vaccine or antiviral agent is currently available. Attempts to control the spread of ASFV are dependent on early detection, adherence to biosecurity measures, and culling of infected herds. However, an effective antiviral agent may be used in lieu of or in conjunction with a vaccine to effectively curb ASFV outbreaks. The dose-dependent antiviral activities of two amidate prodrugs (compounds 1a and 1b) of -2-alkylated 3-fluoro-2-(phosphonomethoxy)propyl cytosine [()--2-alkylated FPMPC] against ASFV isolates of four different genotypes were determined. Both compounds were found to inhibit ASFV progeny virus output by >90% at noncytotoxic concentrations (<25 μM) in primary porcine macrophages. Analysis of viral transcription and viral protein synthesis indicated that these acyclic nucleotide analogues inhibited late gene expression. Interestingly, time-of-addition studies suggest different viral targets of the compounds, which may be attributed to their differing amino acid prodrug moieties. In view of their promising antiviral activity, these nucleotide analogues merit further evaluation as potential prophylactic and/or therapeutic agents against ASFV infection and their antiviral efficacy should be considered. African swine fever virus is a highly contagious hemorrhagic viral disease. Since its transcontinental spread to Georgia in 2007, ASFV has continued to spread across the globe into countries previously without infection. It is responsible for substantial losses in the domestic pig population and presents a significant threat to the global swine industry. Despite ongoing efforts, there are no vaccines currently available; in their absence, antiviral agents may be a viable alternative. The significance of our research is in identifying the pan-genotype antiviral activity of prodrugs of -2-alkylated 3-fluoro-2-(phosphonomethoxy)propyl cytosine, which will drive further research on the development of these compounds as antivirals against ASFV.
非洲猪瘟病毒(ASFV)引起一种高度传染性的出血性疾病,家猪的病死率接近 100%。ASFV 导致了巨大的经济损失,但尽管正在进行持续努力,目前尚无疫苗或抗病毒药物可用。控制 ASFV 传播的尝试依赖于早期检测、遵守生物安全措施和扑杀受感染的畜群。然而,有效的抗病毒药物可用于替代或与疫苗联合使用,以有效遏制 ASFV 爆发。两种酰胺前药(化合物 1a 和 1b)对四种不同基因型的 ASFV 分离株的剂量依赖性抗病毒活性进行了测定。在原代猪巨噬细胞中,两种化合物在非细胞毒性浓度(<25μM)下均能抑制 ASFV 子代病毒的产生,抑制率超过 90%。病毒转录和病毒蛋白合成分析表明,这些无环核苷酸类似物抑制晚期基因表达。有趣的是,添加时间研究表明这些化合物的病毒靶标不同,这可能归因于它们不同的氨基酸前药部分。鉴于它们有希望的抗病毒活性,这些核苷酸类似物值得进一步评估,作为预防和/或治疗 ASFV 感染的潜在药物,应考虑其抗病毒功效。非洲猪瘟病毒是一种高度传染性的出血性病毒性疾病。自 2007 年跨大陆传播到格鲁吉亚以来,ASFV 继续在全球范围内传播到以前没有感染的国家。它导致家猪数量的大量损失,并对全球养猪业构成重大威胁。尽管正在进行持续努力,但目前尚无疫苗可用;在没有疫苗的情况下,抗病毒药物可能是一种可行的替代方法。我们研究的意义在于确定 -2-烷基化 3-氟-2-(膦酸甲氧基)丙基胞嘧啶前药的泛基因型抗病毒活性,这将推动进一步研究这些化合物作为 ASFV 抗病毒药物的开发。